伯明翰髋关节表面置换术25年随访结果
该研究延长了首例连续130例患者(144髋)伯明翰髋关节表面置换术(BHR)队列的随访至25年,总体假体生存率为83.50%(95%CI 0.79至0.90),男性患者25年生存率为89.5%(95%CI 0.83至0.96),女性为66.9%(95%CI 0.51至0.83)。作者认为金属对金属(MoM)BHR为全髋关节置换术(THA)提供了持久替代方案,尤其在希望维持高功能水平的年轻男性骨关节炎患者中。
要点
- 25年总体假体生存率为83.50%(95%CI 0.79至0.90),风险人数为79。
- 男性25年生存率为89.5%(95%CI 0.83至0.96),女性为66.9%(95%CI 0.51至0.83)。
- 10至25年间额外发生10例失败:金属碎屑不良反应4例、假体周围股骨颈骨折5例、无菌性松动1例。
核心结论
- 作者认为,使用BHR的金属对金属髋关节表面置换术为全髋关节置换术提供了持久的替代方案,尤其在希望维持高功能水平的年轻男性骨关节炎患者中。
- 作者指出,这些结果与全髋关节置换术的最佳结果相比具有优势。
研究设计与样本
- 研究为单设计师外科医生连续队列的25年随访扩展报告,纳入最初连续144例表面置换手术(130例患者),涵盖所有适应证。
- 所有手术于1997年8月至1998年5月间进行,手术时平均年龄为52.1岁(标准差9.93;范围17至76),包括37例女性患者(28.5%)。
- 失败定义为因任何原因对任一组件进行翻修,采用Kaplan-Meier生存分析,并进行血清金属离子水平、X线片和牛津髋关节评分(OHS)的常规随访。
主要发现
- 25年时总体假体生存率为83.50%(95%CI 0.79至0.90),风险人数为79。
- 男性患者25年生存率为89.5%(95%CI 0.83至0.96),女性患者为66.9%(95%CI 0.51至0.83)。
- 10至25年间额外发生10例失败,涉及金属碎屑不良反应4例、假体周围股骨颈骨折5例、无菌性松动1例。
- 中位铬水平为49.50 nmol/l(四分位距34至70),中位血清钴水平为42 nmol/l(四分位距24.50至71.25)。
- 末次随访时中位OHS为35(四分位距10至48),25年研究期间29例患者死亡,25年患者生存率为75.10%(95%CI 0.67至0.83)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The Birmingham Hip Resurfacing (BHR) was introduced in 1997 to address the needs of young active patients using a historically proven large-diameter metal-on-metal (MoM) bearing. A single designer surgeon's consecutive series of 130 patients (144 hips) was previously reported at five and ten years, reporting three and ten failures, respectively. The aim of this study was to extend the follow-up of this original cohort at 25 years. METHODS: The study extends the reporting on the first consecutive 144 resurfacing procedures in 130 patients for all indications. All operations were undertaken between August 1997 and May 1998. The mean age at operation was 52.1 years (SD 9.93; 17 to 76), and included 37 female patients (28.5%). Failure was defined as revision of either component for any reason. Kaplan-Meier survival analysis was performed. Routine follow-up with serum metal ion levels, radiographs, and Oxford Hip Scores (OHSs) was undertaken. RESULTS: Overall implant survival was 83.50% (95% confidence interval (CI) 0.79 to 0.90) at 25 years, and the number at risk was 79. Survival in male patients at 25 years was 89.5% (95% CI 0.83 to 0.96) compared to 66.9% for female patients (95% CI 0.51 to 0.83). Ten additional failures occurred in the period of ten to 25 years. These involved an adverse reaction to metal debris in four patients, a periprosthetic femoral neck fracture affecting five patients, and aseptic loosening in one patient. The median chromium levels were 49.50 nmol/l (interquartile range (IQR) 34 to 70), and the median cobalt serum levels were 42 nmol/l (IQR 24.50 to 71.25). The median OHS at last follow-up was 35 (IQR 10 to 48). During the 25-year study period, 29 patients died. Patient survival at 25 years was 75.10% (95% CI 0.67 to 0.83). CONCLUSION: This study demonstrates that MoM hip resurfacing using the BHR provides a durable alternative to total hip arthroplasty (THA), particularly in younger male patients with osteoarthritis wishing to maintain a high level of function. These results compare favourably to the best results for THAs.
引用
- Nandra RS, Elnahal WA, Mayne A, et al. Birmingham Hip Resurfacing at 25 years. Bone Joint J. 2024. PMID: 38821495. doi:10.1302/0301-620X.106B6.BJJ-2023-1064.R1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。